Active Ingredient History
Bosentan is a dual endothelin receptor antagonist important in the treatment of pulmonary artery hypertension (PAH). It is licensed in the United States, the European Union and other countries by Actelion Pharmaceuticals for the management of PAH under the trade name Tracleer®. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. Bosentan competitively antagonizes the binding of 125I-labeled ET-1 to human vascular smooth muscle cells (predominantly ETA receptors) with an inhibition constant (Ki ) of 4.7 nM and to human placenta membranes (predominantly ETB receptors) with a Ki of 95 nM. Furthermore, bosentan is specific for endothelin receptors and does not interfere with the binding of a variety of peptides, neurotransmitters, growth factors, or eicosanoids to their receptors. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Hypertension, Pulmonary (approved 2001)
Altitude (Phase 1)
Anemia, Sickle Cell (Phase 3)
Asthma (Phase 2)
Blood Flow Velocity (Phase 1)
Bosentan (Phase 4)
Connective Tissue Diseases (Phase 3)
Dermatology (Phase 2)
Diabetes Mellitus (Phase 1)
Diabetes Mellitus, Type 2 (Phase 4)
Eisenmenger Complex (Phase 4)
Ethnic and Racial Minorities (Early Phase 1)
Fever (Phase 1/Phase 2)
Glaucoma (Phase 1)
Hand Injuries (Phase 2)
Healthy Volunteers (Phase 1)
Heart Defects, Congenital (Phase 2)
Heart Diseases (Phase 2)
Heart Failure (Phase 1/Phase 2)
Heart Failure, Diastolic (Phase 3)
Heart Septal Defects, Atrial (Phase 3)
Heart Ventricles (Phase 2)
Hepatopulmonary Syndrome (Phase 2)
Hypertension ()
Hypertension, Pulmonary (Phase 4)
Hypoplastic Left Heart Syndrome (Phase 2)
Idiopathic Pulmonary Fibrosis (Phase 4)
Liver Cirrhosis (Phase 2)
Lung Diseases, Interstitial (Phase 4)
Melanoma (Phase 2)
Mitral Valve Stenosis (Phase 1/Phase 2)
Neoplasms (Phase 1)
Optic Neuropathy, Ischemic (Phase 3)
Pancreatic Neoplasms (Phase 1)
Pneumonia (Phase 4)
Port-Wine Stain (Phase 2)
Pulmonary Arterial Hypertension (Phase 4)
Pulmonary Disease, Chronic Obstructive (Phase 2)
Pulmonary Fibrosis (Phase 2/Phase 3)
Sarcoidosis (Phase 2/Phase 3)
Scleroderma, Systemic (Phase 4)
Sleep Apnea, Obstructive (Phase 2)
Sleep Apnea Syndromes (Early Phase 1)
Therapeutic Equivalency (Phase 1)
Tourniquets (Phase 4)
Tricuspid Atresia (Phase 2)
Ulcer (Phase 4)
Vascular Diseases (Early Phase 1)
Vasoconstriction (Early Phase 1)
Vasodilation (Early Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
